NAV

CGC-11047

Identification

Generic Name
CGC-11047
DrugBank Accession Number
DB05722
Background

CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 511.64
Monoisotopic: 508.0994412
Chemical Formula
C14H39Cl7N4
Synonyms
Not Available
External IDs
  • CGC 11047
  • CGC-11047
  • SL 11047
  • SL 47
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in lymphoma (unspecified), macular degeneration, prostate cancer, and solid tumors.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

CGC-11047 is a polyamine analog with anti-proliferative properties. Polyamines are cell components considered essential for cell proliferation and differentiation. They are believed to work by displacing polyamines from their natural binding sites and preventing cell replication. CGC-11047 has been very well-tolerated in Phase I clinical trials and has demonstrated promising activity in patients with advanced disease.

Mechanism of action

The mechanism of action of CGC-11047 is unknown but it is believed to block the growth of cancer cells by blocking the production of new DNA in the cancer cells.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
HU43305R7O
CAS number
206991-64-2
InChI Key
MNJCMBNLXQCNHO-YGGCHVFLSA-N
InChI
InChI=1S/C14H32N4.4ClH/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2;;;;/h5-6,15-18H,3-4,7-14H2,1-2H3;4*1H/b6-5-;;;;
IUPAC Name
SMILES
Cl.Cl.Cl.Cl.CCNCCCNC\C=C/CNCCCNCC

References

General References
  1. Mitchell JL, Thane TK, Sequeira JM, Marton LJ, Thokala R: Antizyme and antizyme inhibitor activities influence cellular responses to polyamine analogs. Amino Acids. 2007 Aug;33(2):291-7. Epub 2007 Apr 6. [Article]
  2. Lima e Silva R, Kachi S, Akiyama H, Shen J, Hatara MC, Aslam S, Gong YY, Khu NH, Lauer TW, Hackett SF, Marton LJ, Campochiaro PA: Trans-scleral delivery of polyamine analogs for ocular neovascularization. Exp Eye Res. 2006 Nov;83(5):1260-7. Epub 2006 Sep 6. [Article]
  3. Loussouarn G, Marton LJ, Nichols CG: Molecular basis of inward rectification: structural features of the blocker defined by extended polyamine analogs. Mol Pharmacol. 2005 Aug;68(2):298-304. Epub 2005 May 4. [Article]
PubChem Substance
347910197
ChemSpider
7998132
ChEMBL
CHEMBL4296681

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentProstate Cancer1
1CompletedTreatmentAge - Related Macular Degeneration (AMD)1
1CompletedTreatmentCancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.106 mg/mLALOGPS
logP1.13ALOGPS
logS-3.4ALOGPS
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at November 18, 2007 18:27 / Updated at May 10, 2021 12:36